Hereditary hemochromatosis, one of the commonest genetic disorder in Caucasians, is mainly associated to homozygosity for the C282Y mutation in the HFE gene, which is highly prevalent (allele frequency up to near 10% in Northern Europe) and easily detectable through a widely available "first level" molecular test. However, in certain geographical regions like the Mediterranean area, up to 30% of patients with a HH phenotype has a negative or non-diagnostic (i.e. simple heterozygosity) test, because of a known heterogeneity involving at least four other genes (HAMP, HJV, TFR2, and SLC40A1). Mutations in such genes are generally rare/private, making the diagnosis of atypical HH essentially a matter of exclusion in clinical practice (from here the term of "non-HFE" HH), unless cumbersome traditional sequencing is applied. We developed a Next Generation Sequencing (NGS)-based test targeting the five HH genes, and applied it to patients with clinically relevant iron overload (IO) and a non-diagnostic first level genetic test. We identified several mutations, some of which were novel (i.e. HFE W163X, HAMP R59X, and TFR2 D555N) and allowed molecular reclassification of "non-HFE" HH clinical diagnosis, particularly in some highly selected IO patients without concurring acquired risk factors. This NGS-based "second level" genetic test may represent a useful tool for molecular diagnosis of HH in patients in whom HH phenotype remains unexplained after the search of common HFE mutations. 
algorithms included in guidelines [14, 15] . On the other hand, soon after the discovery of the HFE gene in 1996 [16] , it has become clear that HH is a genetically heterogeneous disorder, particularly in the Mediterranean area where up to near 30% of patients have a negative or "non-diagnostic" (i.e., C282Y and H63D simple heterozygosity) first level genetic test [17] . Rare mutations in the HFE gene itself, and/or in additional four genes encoding hepcidin (HAMP) [18] , its receptor ferroportin (SLC40A1) [19, 20] , or critical modulators of the iron-sensing machinery controlling hepcidin like type 2 transferrin receptor (TFR2) [21, 22] , and hemojuvelin (HJV) [23, 24] , have also been associated to HH. Such conditions are often collectively designated as "non-HFE" HH [25, 26] . Of note, mutations in the abovementioned genes are typically "private," i.e., limited to just one family and/or few individuals, requiring DNA sequencing for establishing a possible molecular diagnosis. In clinical practice, "non-HFE" HH is still essentially a diagnosis of exclusion, which is made after a negative first level genetic test in subjects with clinical, biochemical, instrumental, and pathological findings suggesting primary iron overload. Only relatively few cases have been molecularly characterized at referral centers through traditional sequencing, which was hampered by time-consuming and costs, until recently. Recent breakthrough in the development of novel genomic technologies for high-throughput DNA sequencing, collectively known as "next generation sequencing" (NGS), have now the potential of revolutionizing the molecular diagnosis of inherited diseases [27] . This holds the promise of a significant impact on clinical care [28] , with unprecedented accuracy, rapidity, and at constantly declining costs [29] .
Here we describe the development of a NGS-based "second level" genetic test that simultaneously analyzes all the five hemochromatosis genes, whose performance was evaluated in patients attending our referral clinic because of the presence of relevant biochemical signs of IO and nondiagnostic first level genetic test, suggesting a possible atypical HH.
Methods
Patients. The newly developed second level, NGS-based, genetic test for HH was applied to a total of 106 subjects. For this study we selected DNA samples from patients attending our Regional Referral Centre for Iron Disorders at the Azienda Ospedaliera Universitaria Integrata of Verona (http://www.gimferverona.org). All patients (n 5 34; mean age 51.3 years, CIs: 47.5-55.2 years; 82.3% males) had relevant biochemical signs of iron overload (i.e., mean serum ferritin 1,810 mg L
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, CIs: 1,369-2,259 mg L
; mean ransferring saturation 62.3%, CIs: 54.3-70.2%), confirmed by liver iron content (LIC) measured through magnetic resonance (MR), and/or liver biopsy showing the typical periportal iron deposition. Patients were categorized into three groups. Group 1 (n 5 8) included patients having IO without apparently relevant cofactors (i.e., metabolic syndrome, HCV infection, alcohol abuse) and with non-diagnostic first level genetic test, defined as above. From a clinical point of view, these patients were provisionally considered affected by "non-HFE" HH with high probability. Group 2 (n 5 16) included patients with a non-diagnostic first level genetic test and some acquired cofactors, which nevertheless were deemed disproportionate (i.e., possibly unable to fully explain the IO phenotype) by clinical judgment. In such patients, the presence of other HH genetic variants could be theoretically anticipated as potential contributors to better explain the clinical/biochemical phenotype. Group 3 (n 5 10) included historical patients attending our referral center with known rare mutations previously detected by traditional sequencing [19, 22, 30] . Such patients were included in the study as "methodological controls", i.e. to confirm the ability of the new test to catch the presence of the known genetic variants in the HH genes. Finally, a nearly double number (n 5 72) of age-and sex-matched subjects with documented normal iron biochemical parameters (i.e., serum ferritin levels between 30 and 200 or 300 mg L 21 in females and males, respectively) were included in this study as "true controls." All patients and controls gave written informed consent to DNA analyses, according to study protocols approved by the Ethical Committee of the Azienda Ospedaliera Universitaria Integrata di Verona.
Sample preparation. Genomic DNA was extracted using kit (Promega, Madison, WI). DNA quality was determined on a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA) while concentration was measured using Qubit dsDNA assay kit with Qubit fluorometer (Life Technologies, Carlsbad, CA). DNA integrity was assessed by gel electrophoresis on agarose gel (1%).
Target capture and sequencing. Capture of exonic regions of the 5 HH genes (HFE, HFE2, TFR2, HAMP, and SLC40A1) was performed starting from 225 ng of genomic DNA using a custom design HaloPlex TM Target Enrichment 1-500 kb Kit (Agilent Technologies, Santa Clara, CA) according to manufacturer instructions. Of note, this approach has recently been recommended for high-coverage capturing of regions spanning 100-500 Kb, particularly when relatively large batches have to be examined [31] . Library quality was determined using the Agilent High Sensitivity DNA kit on the Agilent 2100 bioanalyzer, and the quantity was measured using Qubit dsDNA assay kit with Qubit fluorometer (Life Technologies, Carlsbad, CA) and by quantitative PCR using the KAPA Library Quantification kit (Kapa Biosystems). Libraries were pooled at equimolar concentrations and sequenced with TruSeq PE Cluster Kit v3 and TruSeq SBS Kit v3 (Illumina, San Diego, CA) on Illumina HiSeq 1000 sequencer (Illumina, San Diego, CA) generating 100-bp paired-end reads at average target coverage of 1000X for captured regions.
Data analysis. Illumina adapter sequences were removed from sequence reads using Scythe software using default parameters (v. 0.994; https://github.com/vsbuffalo/scythe). Low quality read ends were trimmed using Sickle software (https:// github.com/vsbuffalo/scythe). Reads were mapped against reference human genome version 19 (HG19) using BWA (Burrows Wheeler Aligner, version 0.7.10). Mappings and portion of mappings outside expected amplicons were removed using custom scripts. Duplicate PCR reads were removed using Picard, base quality scores were recalibrated using Genome Analysis Toolkit (GATK, version 3), and alignments near putative insertion/deletions were refined with GATK. Variants were called using Unified Genotyper module from GATK. Variant calls that failed to pass the following filters were eliminated from the call set: (i) MQ0 4 && ((MQ0/(1.0 * DP)) > 0.1), (ii) DP < 5, (iii) QUAL < 30.0, (iv) QD < 5.0. Coding and splice variants were annotated using the SNP & Variation Suite software (Version 8; Golden Helix, Bozeman, MT). The potential functional impact of identified variants was assessed using three different predictive algorithms, i.e. Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping version 2 (PolyPhen2 HumaVar), and MutationTaster (MT). The variants of interest were confirmed by traditional Sanger sequencing using a CEQ 8000 capillary sequencer and GenomeLab DTCS Quick Start kit (Beckman Coulter, Indianapolis, IN). When possible, some of the genetic variants that appeared most interesting were further studied by in silico modeling, as reported [32] . Methodological details and ad hoc references are reported in Supporting Information [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] .
Results

Genetic variants and literature review
Supporting Information Table SI summarizes the variants found through NGS that survived rigorous filtering, in addition to the known HH associated HFE mutations (C282Y, H63D, S65C), and the known mutations previously found in methodological controls. For sake of completeness, we report also the variants found only in controls, which could be useful for comparison with future reports and for databases compilation [33, 34] . Among the listed variants, five were apparently new, i.e. not reported in the following databases: dbSNPs (http://www.ncbi.nlm.nih.gov/SNP/), 1,000 genome (http://www.1000genomes.org/category/sequence), OMIM (http://www.ncbi.nlm.nih.gov/omim), and ESP Databases (http://evs.gs.washington.edu/EVS/). We also checked a very recent paper reporting a catalogue of all hemochromatosis associated variants [35] . Two out of the new mutations, i.e., the H274fs in SLC40A1 and M45fs in TFR2 were found in control subjects. The SLC40A1 H274fs was found in a 43-year-old man with serum ferritin of 199 mg L
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. Although no prediction could be inferred by the three predictive algorithms (Supporting Information Table SI), given that ferroportin disease is the only dominant non-HFE HH subtype, this variant is likely non pathogenic. The same applies to the TFR2 M54fs, i.e., no useful information from the predictive algorithms, but since type 3 HH is autosomal recessive we cannot draw any conclusion about its possible pathogenic role.
The three other novel private variants found only in patients from group 1, which could be considered very likely pathogenic, are described in detail below along with individuals' clinical data (Table I) .
A sixth patient from group 1 with history of consanguinity was found homozygous for the TFR2 N241I mutation. This variant has been previously reported as pathogenic by others [36] , since it was found in a young male whose HH was clinically diagnosed at the age of 17 years. Our data are also consistent with a highly penetrant mutation, since our patient was a female whose HH was clinically diagnosed during the fertile period (at the age of 35 years) because of sustained increase of transaminases, 100 percent transferrin saturation, and a liver biopsy showing iron overload and advanced fibrosis (Table I , patient ID 5 #06). In this patient we also found a SLC40A1 variant (rs11568344, Supporting Information Table SI), which was already reported as a benign polymorphism by others [37] .
The TFR2 rs41295942 variant (resulting in mutation R581H was previously described by early reports using traditional sequencing, with contrasting or biased results [38] [39] [40] . It was also specifically investigated as a potential modifier of the C282Y genotype in a recent report [41] , but no effect was found. In our study, this variant was found in homozygosity in a control subject (a 47-year-old male with serum ferritin of 167 mg L
). This finding appears to definitively rule out a possible pathogenic role of this TFR2 variant. The HJV A197G variant (rs7540883) that we found in heterozygosity in a control subject was also previously reported by others [37] , but without a definite conclusion on its possible pathogenetic role. It was only "possibly damaging" according PolyPhen2, and benign according to SIFT and MT, which seems more likely. Other variants already annotated/reported [42, 43] and classified as benign/polymorphisms are reported in Supporting Information Table SI.
Novel private mutations with high probability of being pathogenic Three interesting novel variants were found in patients from group 1 ( Table I) . Patient #03 carried a stop-codon mutation (R59X) in the HAMP gene. Of note, the Arginine at position 59 is located immediately upstream the sequence containing the hepcidin-25 mature peptide (Fig. 1) . Thus, this mutation results in the synthesis of a pre-prohepcidin that cannot be processed into the functional peptide. This patient was diagnosed at the age of 48 years because of altered iron parameters (serum ferritin >1,000 mg L
, transferrin saturation >70%) and substantial iron accumulation at MRI, but he was clinically asymptomatic and refused liver biopsy (Table I) . At the first level genetic test he was only heterozygous for the HFE H63D variant. Thus, after NGS the patient could be reclassified as an example of HH due to digenic inheritance, i.e. the presence of two or more variants in distinct genes involved in the same pathway (hepcidin sensing/production) sufficient to give rise to the clinical disease [44] .
Patient #02 was also a simple H63D heterozygous at first level genetic test, which clearly did not explain a highly penetrant HH phenotype with advanced fibrosis at liver biopsy performed at the age of 39 years (Table I) . NGS revealed a new stop-codon mutation in the HFE gene (W163X), whose modeling is reported in Fig. 2 . According to in silico analysis, the mutation determines a dramatic change of protein structure, with the truncated protein being predicted to lack some amino acids critical for the surface interaction between HFE and transferrin receptor 1 (TFR1). It could affect also other interactions, e.g. BMP type I receptor ALK3). Such effects would eventually prevent the signaling that gives rise to hepcidin production. The final functional effect of this mutation can be considered similar to that of the C282Y mutation, which has been reported to prevent the correct membrane localization of HFE protein [45] . Thus, the molecular diagnosis in this patient previously classified as likely affected by "non-HFE" HH, was indeed "atypical" type 1 (or HFE-related) HH due to compound heterozygosity for a novel and a known mutation (W163X/H63D). Patient #05 was a 58-year-old male with marked hyperferritinemia and substantial liver iron deposition at MRI (Table I) , which, in absence of cofactors, were not explained by the H63D homozygosity at first level genetic test. NGS revealed a new (D555N) TFR2 mutation that was predicted as pathogenetic by all three algorithms (Supporting Information Table SI) , and whose modeling is reported in Supporting Information Fig. S1 . Briefly, the mutation is predicted to change substantially the electrostatic properties of a putative calcium binding cavity on protein crystal structure, through the substitution of a negative charge with a positive one (Supporting Information Fig.  S1 ). This patient could be also reclassified as HH likely due to digenic HFE/TFR2 inheritance.
Overall, including the previously reported TFR2 N241I mutation, the NGS-based second level genetic test allowed to find a plausible molecular diagnosis in four out of seven patients from group 1, i.e., those previously classified provisionally as "non-HFE HH."
It is also noteworthy that no potentially pathogenic variant was found in patients from group 2, i.e., IO patients who were a priori less likely to have pathogenic mutations because of the co-presence of acquired cofactors.
Finally, regarding the performance of our second level genetic test, all the mutations previously described in the "methodological" group, including HJV N196K [30] , TFR2 AVAQ 594-597 deletion [22] , and SLC40A1 L233P/I152F [19] , were confirmed by NGS. Moreover, all the new potentially causative variants detected by NGS were confirmed by Sanger sequencing (Supporting Information  Fig. S2 ).
Discussion
This study, along with a very similar one in Australian patients recently published by McDonald and colleagues [40] , further illustrates the usefulness of an NGS-based approach test for the molecular diagnosis in patients with a provisional diagnosis of "non-HFE" HH. Indeed, in highly selected patients attending our referral center for Iron Disorders with a unexplained HH phenotype, because of either non-diagnostic 1st level genetic test or absence of acquired risk factors for nongenetic IO, we could obtain a plausible molecular explanation in five out of eight, finding three novel variants in HFE, HAMP, and TFR2. The same test also allowed us to detect a rare SCL40A1 mutation in one patient with a distinct phenotype, who has been described separately (Ferbo L, manuscript under revision). A limitation lies on the fact that NGS was exonic, so there still could be causative mutations in the analyzed genes within non-exonic sequences. Anyway, similarly to our results, McDonald et al. [40] , using a different NGS platform and an enlarged panel of genes possibly involved in a broad range of iron disorders (n 5 39), were able to identify a likely causal mutation (in HJV, SCL40A1, HFE, or TFR2, but not in HAMP) in five out of eight patients with "atypical IO." Of note, notwithstanding the broad panel used, even in their study some patients with a HH phenotype remained molecularly "unexplained" after extensive NGS. While, of course, no NGS method, whatever the platform used, can ensure 100% sensitivity in detecting causal mutations, it is tempting to conclude that some still unknown genes could be involved in determining HH-like clinical phenotypes in humans. These genes could be eventually detected by using other NGS-based techniques like whole genome/ exome sequencing [27] , however their application is presently limited not only by costs, but also by difficulties in interpretation and ethical problem in reporting incidental findings [46] .
Until now, the diagnosis of atypical or "non-HFE" HH is largely a diagnosis of exclusion, and our knowledge on these conditions is mainly based on individual studied by traditional Sanger sequencing. Current recommendations suggest a stepwise approach for the molecular diagnosis of atypical systemic iron overload disorders, in which sequencing should be made initially according to clinical features (i.e., prioritizing HJV and HAMP in patients with early onset IO) [5, 14] . While this is reasonable, it is time consuming and does not take appropriately into account the possible occurrence of digenic inheritance [47] . This new approach of simultaneous NGS-based sequencing of the five HH genes at a reasonable cost will clearly simplify the molecular diagnosis in a near future. Moreover, it will allow to expand/refine knowledge on the clinical features of the distinct HH subtypes. For example, based on the few cases reported until now, there is some controversy regarding whether or not type 3 (TFR2-related) HH has an earlier (or intermediate) onset as compared to type 1 [36] . Similarly, it is unclear whether or not type 4 HH (SLC40A1-related or ferroportin disease) is a relatively mild form of HH with low incidence of overt cirrhosis and HCC [20] . A widespread application of NGS-based molecular diagnosis is expected to substantially increase the accuracy of HH molecular diagnosis, allowing, preferably through the creation of ad hoc registries, a more precise phenotypic description of HH subtypes.
Noteworthy, we did not find any relevant mutation in patients from group 2, i.e., those with IO possibly out of proportion with Receptor (TFR) and Beta-2-Microglobulin (B2M) crystal structure (PDB accession code: 1DE4) before and after the mutation HFE W163*. HFE (blue), TFR (red) and B2M (brownish) proteins before the mutation. (B) Putative HFE's fragment lost (light blue regions) after the mutation of TRP163 to a stop codon. These regions, when present, are actively involved in functional interactions with their molecular partners. Noteworthy, it is otherwise likely that, because of Nonsense-Mediated mRNA Decay (NMD), no HFE protein is produced when TRP163 change a stop codon. NMD is a translation-coupled mechanism that eliminates mRNAs containing premature translation-termination codons (PTC). In mammalian cells, NMD is also linked to pre-mRNA splicing, as in many instances strong mRNA reduction occurs only when the PTC is located upstream of an intron [61] . This picture is thus aimed at showing, in a structural context, the regions that are lost upon mutation.
respect to the burden of acquired risk factors. The role of the copresence of variants in the iron-sensing proteins (HJV, HAMP, TFR2) has been previously investigated in C282Y homozygotes as possible genetic cofactors able to increase clinical expression, but they have been detected only rarely in sporadic patients [30, [48] [49] [50] . Accordingly, our results suggest that variants in such genes are unlikely to act as modifiers also in patients with IO due to acquired risk factors. Of course, we cannot exclude in such patients the influence of other genetic modifiers not included in our restricted diagnostic panel [51, 52] . Nonetheless, this underlines the critical importance of an accurate clinical selection before ordering any genetic test, which should be done only in subjects with the highest pretest probability. In our experience, while NGS-based methods clearly represent a major technical advance, interpretation of the clinical relevance of molecular data remains a difficult task, requiring close and repeated contacts among clinicians, molecular analysts, and bioinformatic experts. Nonetheless, our study provides further evidence of the usefulness of a NGS-based approach targeting a specific gene panel for the molecular diagnosis of patients clinically classified as "atypical" or non-HFE HH after first level genetic testing.
